SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple's stock is trending downwards as the market reacts negatively to the company's latest product announcements, particularly the new iPhone. The community expresses concerns around lack of innovation and whether the new features justify an upgrade, contributing to a sell-off. Many traders believe the stock predictably declines following these events.

QMMM Holdings Ltd. engages in the provision of digital advertising services. It offers interactive design, animation, art-tech and virtual technologies used in commercial campaigns. It has worked with domestic and international banks, real estate developers, amusement parks, international sports apparel, footwear brands, luxury cosmetic products, and international brands. The company was founded by Bun Kwai on July 29, 2022 and is headquartered in Hong Kong.

QMMM Holdings Ltd. - Ordinary Shares - Class A

QMMM Holdings Ltd.

QMMM is trending due to a reported announcement regarding a $100 million crypto treasury plan, sparking significant community discussion around potential investment strategies and comparisons to other recently volatile stocks. The stock's trading activity is marked by multiple trading halts, and investors are actively debating the potential for further gains versus the risk of a pump and dump scenario, particularly given its connections to Chinese markets and related news. Overall, the community's focus is on the stock's volatility, crypto angle, and the possibility of a short squeeze.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending following news of a significant AI infrastructure deal with Microsoft, sparking considerable enthusiasm among investors. Community discussions revolve around the potential for further growth and partnerships, with some speculating on new price targets. Despite some profit-taking, the overall sentiment appears bullish due to the deal's potential impact on the company's revenue and market position in the high-performance computing sector.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending as positive Medicare Advantage ratings news sparks optimism and a significant rally. Community members are actively discussing potential price targets and the possibility of a short squeeze, while acknowledging broader factors like Warren Buffett's investment and the potential for further upside.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities Inc. ($ASST) is trending as investors anticipate the results of a special meeting regarding a potential merger, with speculation building around a possible short squeeze and comparisons being drawn to similar plays like $OCTO. The community is actively discussing potential price targets and the impact of a merger approval on the stock's valuation. Many are optimistic about the company's future as a Bitcoin treasury.

CaliberCos, Inc. operates as an asset management firm. It provides various support services including asset management & fund set-up services, as well as lending support, construction & development management, and real estate brokerage services. The company was founded by John Christopher Loeffler II and Jennifer Schrader in January 2009 and is headquartered in Scottsdale, AZ.

CaliberCos Inc - Ordinary Shares - Class A

CaliberCos Inc 

CaliberCos ($CWD) is trending due to discussions around a recent volatile trading session, with community members debating the merits of holding versus selling. The stock's earlier surge, reportedly fueled by the company's initial purchase of Chainlink tokens, has given way to concerns about dilution and insider selling, sparking a battle between bulls and bears. Some traders are pointing to other stocks as potential plays, drawing comparisons to previous high-momentum tickers.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo ($DUOL) is trending downwards as the community discusses concerns over increased competition from AI-powered language tools, including Apple's new live translation feature for AirPods and Google's language learning updates to Google Translate. Some investors worry that these technologies could make Duolingo's services obsolete, while others remain optimistic about Duolingo's long-term prospects due to its gamified learning approach and established brand.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

Anavex Life Sciences is trending amid ongoing discussions around blarcamesine's potential EMA approval, expected in early 2026, with community members highlighting data presented at HC Wainwright 2025 showing significant reduction in Alzheimer's decline compared to placebo. The community is weighing both the strong clinical and regulatory momentum against concerns raised by critics regarding previous trial results, while also discussing potential buyout offers and short squeeze opportunities.

Centene Corp. is a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment includes the Temporary Assistance for Needy Families program, Medicaid Expansion programs, the Aged, Blind or Disabled program, the Children's Health Insurance Program, Long-Term Services and Supports, Foster Care, Medicare-Medicaid Plans, which cover beneficiaries who are dually eligible for Medicaid and Medicare, and other state-based programs. The Medicare segment consists of Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans, and Medicare Prescription Drug Plans. The Commercial segment is involved in the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. The Other segment refers to pharmacy operations, Envolve Benefit Options’ vision and dental services, clinical healthcare, behavioral health, the TRICARE program, and corporate management companies. The company was founded in 1984 and is headquartered in St. Louis, MO.

Centene Corp.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

Iris Energy Ltd

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$XERS Xeris - Beta progress -&gt;

Highlight-&gt;
*By July 2025, Beta Bionics completed dosing for this trial. Preliminary pharmacodynamic data, were supportive of continued development of the glucagon candidate. Full results from the trial are expected in the second half of 2025 and will inform the go-forward development strategy for the glucagon candidate*

The estimated FDA approval timeline for the Xeris-developed liquid-stable glucagon, intended for use in bihormonal iLet system, is approximately 2026–2027. This estimate is based on the completion of PK-PD bridging trials in H2 2025 and a potential NDA submission in late 25 or early 26. The FDA’s  review takes ~ 10 months, 6 months under priority review, assuming no major safety concerns. The full bihormonal system, combining insulin and glucagon, may require additional approval as a combination product, likely extending the timeline to 2027–2028. These projections are approximate and depend on trial outcomes and regulatory review.

Steve Gonzalez

Ronald Dayanghirang

C_Sonnier

TymeTryethTroth

David Evans

PSR Development

Dusan Banicevic

Ambrose Tan

Ellie

StockTwits For Android 

Xeris Biopharma Holdings Inc

 Xeris - Beta progress ->

Highlight->
*By July 2025, Beta Bionics completed dosing for this trial. Preliminary pharmacodynamic data, were supportive of continued development of the glucagon candidate. Full results from the trial are expected in the second half of 2025 and will inform the go-forward development strategy for the glucagon candidate*

The estimated FDA approval timeline for the Xeris-developed liquid-stable glucagon, intended for use in bihormonal iLet system, is approximately 2026–2027. This estimate is based on the completion of PK-PD bridging trials in H2 2025 and a potential NDA submission in late 25 or early 26. The FDA’s  review takes ~ 10 months, 6 months under priority review, assuming no major safety concerns. The full bihormonal system, combining insulin and glucagon, may require additional approval as a combination product, likely extending the timeline to 2027–2028. These projections are approximate and depend on trial outcomes and regulatory review.

Alon Rosenzweig

reminder -&gt;
In May 2024, Xeris Biopharma entered into an exclusive worldwide collaboration and license agreement with Beta Bionics for the development and commercialization of a liquid-stable glucagon formulation using Xeris’s proprietary XeriSol™ technology, intended for use in Beta Bionics bi-hormonal iLet pump systems. The financial terms of the agreement include -&gt;

Development Milestone Payments: Xeris is eligible to receive up to $75 million in development, regulatory, and sales-based milestone payments.  

Royalties: Xeris is entitled to receive low double-digit royalties on future sales of the glucagon product designed for Beta Bionics pumps and pump systems.

Bryan Choong

reminder ->
In May 2024, Xeris Biopharma entered into an exclusive worldwide collaboration and license agreement with Beta Bionics for the development and commercialization of a liquid-stable glucagon formulation using Xeris’s proprietary XeriSol™ technology, intended for use in Beta Bionics bi-hormonal iLet pump systems. The financial terms of the agreement include ->

Development Milestone Payments: Xeris is eligible to receive up to $75 million in development, regulatory, and sales-based milestone payments.  

Royalties: Xeris is entitled to receive low double-digit royalties on future sales of the glucagon product designed for Beta Bionics pumps and pump systems.